Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Pediatrics
N/A
Children
Supportive Care
Not Available
Friedman, Debra
National
Vanderbilt University
08-25-2010
Other
COGALTE05N1
NCT00736749

Eligibility

0 Years
BOTH
NO
Inclusion Criteria:

The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1 * Hodgkin lymphoma ** CCG 5942 ** POG 9425 ** POG 9426 ** AHOD0031 * Brain tumor ** A9961 * Acute lymphoblastic leukemia ** POG 9404 * Osteosarcoma ** POG 9754 * Stem cell transplantation ** ASCT0631D * Rhabdomyosarcoma ** IRS-III ** IRS-IV * Note: For purposes of enrollment onto this study, completion of treatment is defined as the date protocol therapy was terminated as reported (or will be reported) on this patient’s last “Reporting Period Worksheet/CRF” for their frontline therapeutic protocol; patients become eligible as they approach this date, and remain eligible for 180 days following the date that protocol therapy was terminated; early termination of protocol therapy per the decision of the patient, family and/or investigator does NOT preclude enrollment on this study * Note: For purposes of eligibility for ALTE05N1, “early termination of protocol therapy” means that the patient has finished protocol therapy and will not receive further treatment; patients whose therapy is terminated early due to toxicity or who opt out of an end-of-therapy randomization (e.g., randomization to continue with an experimental agent versus [vs.] no further treatment) are eligible because they will not be receiving further therapy; however, a patient who is removed from protocol therapy or opts to discontinue protocol participation early in the course of treatment (e.g., following Induction) is not eligible

The patient must reside in the U.S. on the date of enrollment to ALTE05N1

All patients and/or their parents or legal guardians must sign a written informed consent

All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: